US20090328241A1 - Mitochondrial-nuclear exchanged cells, tissues, organs and animals - Google Patents
Mitochondrial-nuclear exchanged cells, tissues, organs and animals Download PDFInfo
- Publication number
- US20090328241A1 US20090328241A1 US12/486,375 US48637509A US2009328241A1 US 20090328241 A1 US20090328241 A1 US 20090328241A1 US 48637509 A US48637509 A US 48637509A US 2009328241 A1 US2009328241 A1 US 2009328241A1
- Authority
- US
- United States
- Prior art keywords
- disorder
- animal
- disease
- nuclear
- mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 164
- 210000000056 organ Anatomy 0.000 title claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 230
- 201000010099 disease Diseases 0.000 claims abstract description 122
- 208000035475 disorder Diseases 0.000 claims abstract description 108
- 108020005196 Mitochondrial DNA Proteins 0.000 claims abstract description 104
- 108091093105 Nuclear DNA Proteins 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 58
- 238000012216 screening Methods 0.000 claims abstract description 8
- 241000699670 Mus sp. Species 0.000 claims description 100
- 210000004027 cell Anatomy 0.000 claims description 53
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 52
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 210000001161 mammalian embryo Anatomy 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 25
- 230000002438 mitochondrial effect Effects 0.000 claims description 21
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 14
- 210000002257 embryonic structure Anatomy 0.000 claims description 13
- 208000008589 Obesity Diseases 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- 210000000287 oocyte Anatomy 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 238000011813 knockout mouse model Methods 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 9
- 208000026278 immune system disease Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 238000013296 A/J mouse Methods 0.000 claims description 7
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 4
- 210000002308 embryonic cell Anatomy 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 210000003470 mitochondria Anatomy 0.000 description 44
- 238000011735 C3H mouse Methods 0.000 description 32
- 102000054766 genetic haplotypes Human genes 0.000 description 18
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000007800 oxidant agent Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 206010027476 Metastases Diseases 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 10
- 230000001590 oxidative effect Effects 0.000 description 10
- 210000000709 aorta Anatomy 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 9
- 229960001802 phenylephrine Drugs 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229940083618 sodium nitroprusside Drugs 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 6
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 6
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 5
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 5
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 230000003143 atherosclerotic effect Effects 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 230000000923 atherogenic effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 229940049920 malate Drugs 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004898 mitochondrial function Effects 0.000 description 4
- 230000010627 oxidative phosphorylation Effects 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 230000005740 tumor formation Effects 0.000 description 4
- 230000001196 vasorelaxation Effects 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 208000022602 disease susceptibility Diseases 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 2
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000035010 Term birth Diseases 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004536 heart mitochondria Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000004218 vascular function Effects 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101150008892 COIII gene Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 102100028203 Cytochrome c oxidase subunit 3 Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000016903 DNA Polymerase gamma Human genes 0.000 description 1
- 108010014080 DNA Polymerase gamma Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000000258 High-Frequency Hearing Loss Diseases 0.000 description 1
- 101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 231100000885 high-frequency hearing loss Toxicity 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002037 lung adenoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 230000022886 mitochondrial translation Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Definitions
- mtDNA mitochondrial DNA
- OXPHOS oxidative phosphorylation
- rRNAs 12S and 16S
- 22 tRNAs that are required for mitochondrial protein synthesis.
- the mtDNA encoded polypeptide genes are structural subunits for four of the five OXPHOS enzyme complexes (I, III, IV and V).
- the nuclear DNA codes for all other mitochondrial proteins including all four subunits of complex II (succinate dehydrogenase), the mitochondrial DNA polymerase y subunits, the mitochondrial RNA polymerase components, the mitochondrial transcription factor (mtTFA), the mitochondrial ribosomal proteins and elongation factors, and the mitochondrial metabolic enzymes.
- Mitochondria generate energy via OXPHOS which “couples” electron transport with proton translocation for the production of ATP. Mitochondria are also the primary source of endogenous cellular ROS.
- the efficacy of mitochondrial energy and oxidant production is dependent upon a number of factors including local concentrations of both reactive nitrogen and oxygen species, mitochondrial antioxidants, cytokines, electron transport efficiency, metabolic reducing equivalent availability (NADH and FADH2), uncoupling protein (UCP) activities, and overall organelle integrity (damage to membranes, DNA, and proteins).
- cells and animals comprising mitochondrial DNA (mtDNA) from a subject susceptible to a disease or disorder and nuclear DNA (nDNA) from a subject that is not susceptible to the disease or disorder. Also provided are cells and animals comprising mitochondrial DNA (mtDNA) from a subject resistant to a disease or disorder and nuclear DNA (nDNA) from a wild-type subject or a subject that is susceptible to the disease or disorder. Such animals are referred to herein as mitochondrial-nuclear exchanged animals.
- the method comprises selecting an animal susceptible to a disease or disorder, selecting an animal that is not susceptible to the disease or disorder, harvesting pro-nuclear embryos from the animals, enucleating the embryos, transferring the nucleus from the animal that is not susceptible to the disease or disorder to the enucleated embryo of the animal susceptible to the disease or disorder, wherein the embryo has mtDNA from the animal susceptible to the disease or disorder and the NDNA from the animal that is not susceptible to the disease or disorder, and transferring the embryo into an appropriate host and allowing the transferred embryo to develop into a progeny animal, wherein the progeny animal is a mitochondrial-nuclear exchanged animal.
- Also provided is a method of screening for agents useful for treating a disease or disorder comprising the steps of providing a mitochondrial-nuclear exchanged animal comprising mtDNA from an animal susceptible to the disease or disorder and nDNA from an animal not susceptible to the disease or disorder, administering to the animal an agent to be tested, and determining whether the agent prevents or reduces one or more symptoms of the disease or disorder.
- FIG. 1 shows the number of mitochondrial-nuclear exchanges performed resulting in term births, and surviving animals (6 weeks of age). Labels on the X-axis indicate mtDNA haplotype/nuclear genotype.
- PyMT refers to the FVB/N-TgN(MMTVPyMT) mouse.
- C57 refers to the C57BL/6JN1cr mouse.
- FIG. 2A shows a female mitochondrial-nuclear exchanged mouse [C57 mtDNA/FVB/N-TgN(MMTVPyMT) nuclear DNA (nDNA)] at 3 months of age.
- FIGS. 2B and 2C show mtDNA haplotyping gels (Asp I and Bcl I, respectively) to confirm mtDNA haplotype from ear clip DNA; lane 1 is the mouse in FIG. 2A .
- PE phenylephrine
- Ach acetyl
- FIG. 4A shows mice generated from mitochondrial-nuclear exchange. Coat color indicates nDNA genome (C3H—brown, C57—black), which has been confirmed via SNP analysis of 38 markers (Jackson Labs, Bar Harbor, Me.). Numbers on mice indicate mtDNA RFLP analyses in FIGS. 4B and 4C . Number 3, brown coat, is the mouse with nDNA from C3H and mtDNA from C57 mice.
- FIG. 4B shows AspI RFLP analysis verifying mtDNA genotype. PCR products from C57 mtDNAs were cleaved by AspI to yield 274 bp and 111 bp fragments, whereas C3H mtDNAs were uncut (385 bp).
- FIG. 4C shows BclI RFLP analysis verifying mtDNA genotype. PCR products from C57 mtDNAs were uncut (204 bp) whereas C3H mtDNAs were cleaved by BclI to yield 166 bp and 38 bp fragments.
- FIG. 5 is a schematic summarizing the process of creating mitochondrial-nuclear exchanged animals.
- FIG. 6A shows polarographic trace of isolated heart mitochondria.
- State 3 respiration is initiated by addition substrate (glutamate+malate) and ADP (125 nmoles) and total O2 consumption determined until the return to state 4 respiration (occurs when all the ADP is consumed by phosphorylation to ATP).
- Addition of oligomycin abolishes ADP-induced respiratory stimulation which is subsequently relieved by the uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP).
- FCCP uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone
- FIG. 6B is a graph showing the ADP/O ratio of C57BL/6J (C57) and C3H/HeN (C3H) mice relative to C57BL/6J control mitochondria.
- the ADP/O mean+SE over all experiments was C57 ⁇ 2.88+0.05; C3H ⁇ 2.39+0.04).
- Asterisk (*) indicates a significant difference (P ⁇ 0.05) exists from C3H/HeN mouse mitochondria.
- FIG. 7 shows RFLP analysis of mtDNA COIII subunit. Specifically, a gel of AspI restriction digest of 385 bp PCR products from C57 and C3H mice is shown. The C57 mtDNA was cleaved into 274 bp and 111 bp, whereas the C3H mtDNA was not.
- FIGS. 8A and 8B show cytochrome c oxidase activities in C57 and C3H mice. Mitochondria were prepared from whole aortas harvested from 10-week old male C57BL6 and C3H/HeN mice.
- complex IV activity was determined by measuring the oxidation of reduced cytochrome c at 550 nm (37° C.) in isolated mitochondria. Asterisks (*) indicate a significant difference exists between C57 and C3H mitochondria.
- FIG. 8B immunoblot analysis showing the relative level of complex IV subunit II from an aliquot of the samples used for complex IV activity.
- FIG. 9 shows Respiratory Control Ratios (RCR) in C57 and C3H mouse hearts.
- Mitochondria were isolated from age-matched (10 week old) C57and C3H mouse hearts, and oxygen consumption determined in the presence of an electron donor (glutamate/malate) with and without ADP (state 3 and 4 respiration, respectively).
- the bars represent the respiratory control ratio (RCR, equal to state 3 respiration rate divided by state 4 respiration rate); C3H hearts had significantly lower RCR values, indicating that oxygen utilization (in terms of generating ATP) by the mitochondrion is less efficient in the C3H hearts.
- N 3/group.
- FIG. 10 is a bar graph showing mitochondrial membrane potentials in C57 and C3H mice. Mitochondria were prepared from hearts harvested from 10-week old male C57BL6 and C3H/HeN mice (fed chow diets) and JC-1 fluorescence determined at 535 nm and 590 nm emissions on a CytoFluor 4000 fluorometer. Asterisks (*) indicate that a significant difference exists between C57 and C3H mitochondria.
- FIG. 11 shows the effect of diet on mtDNA damage in aortas from C57 and C3H mice.
- Male C57 and C3H mice were fed either chow or high fat diets (4% or 21% fat, respectively) from 6-10 weeks of age.
- DNA was extracted from aortas and QPCR was performed to quantify mtDNA damage.
- Asterisks (* or **) indicate significant differences (P ⁇ 0.05) exist from chow fed C57 or high fat C3H, respectively.
- N 3 per group.
- FIGS. 14A , 14 B and 14 C are graphs showing isometric tension measured in aortic segments from 14-week old male C57 mtDNA /C57 nDNA ; C 3 H mtDNA /C3H nDNA ; C3H mDNA /C57 nDNA ; and C57 mtDNA /C3H nDNA mice.
- indomethacin-treated rings were contracted with phenylephrine (PE) ( FIG. 14A ) followed by addition of acetylcholine (Ach) ( FIG. 14B ).
- Sodium nitroprusside (SNP) was added to contracted rings to determine endothelial independent relaxation ( FIG.
- FIG. 15 shows mtDNA phylogeny derived from known mtDNA sequences from mice (GenBank) also known to have differential susceptibility to cardiovascular disease (CVD).
- CVD susceptibility is characterized as “Very Resistant,” “Resistant,” and “Susceptible” based upon review of the literature; “very resistant” indicates no atherosclerotic lesion formation, “resistant” indicates modest lesion formation relative to the “susceptible” C57 mouse. Amino acid or tRNA changes are indicated next to the location of each mtDNA mutation.
- MtDNA mutations have been linked with human disease. For example, studies have shown that specific mtDNA mutations and haplotypes are associated with increased risk for diseases thought or known to have an environmental component in humans (e.g., deafness, blindness, Alzheimer's disease, diabetes and cancer). Similarly, studies have shown that the mtDNA haplotype can influence tumor growth and age-related deafness in mice. Mitochondrial haplotypes thought to be associated with tightly coupled mitochondria appear to be more prone to certain types of cancer and neurodegenerative diseases associated with oxidative stress and/or somatic mutation.
- mitochondria and the nucleus interact in a manner that ultimately determines how the cell will function and respond to various endogenous and exogenous factors. Consequently, how mitochondria and the nucleus interact determines an individual's susceptibility to disease and the individual's ability to adapt to changes in the environment.
- the provided methods allow exchange of mitochondrial and nuclear genetic materials (i.e., putting a cell nucleus into a cytoplasm containing mitochondria that are typically not associated with that nuclear DNA) and model systems for determining how mtDNA impacts disease development and susceptibility to factors associated with disease risk and adaptation to general environmental changes.
- the provided chimeric models and cells are used to determine the mechanistic and genetic basis of disease susceptibility and resistance (e.g., cardiovascular disease, cancer, diabetes, musculoskeletal, neurological, obesity, aging, fitness, and the like).
- FIG. 5 summarizes the process of creating mitochondrial-nuclear exchanged animals. Specifically, pro-nuclear embryos are harvested from genetically distinct donors (in terms of mitochondrial and nuclear DNAs), enucleated, and the nucleus from one donor is introduced into the enucleated cell of the other, generating an re-nucleated embryo with the nuclear DNA from one strain (e.g., strain B) and the mitochondrial DNAs (e.g., strain A) from the other. These embryos are implanted into surrogate mothers who carry the transgenic embryo to term. The genetic identity of the progeny is confirmed via genotyping tail and ear clips from the offspring.
- pro-nuclear embryos are harvested from genetically distinct donors (in terms of mitochondrial and nuclear DNAs), enucleated, and the nucleus from one donor is introduced into the enucleated cell of the other, generating an re-nucleated embryo with the nuclear DNA from one strain (e.g., strain B) and the mitochondrial
- Females of desired mtDNA-nDNA genotype are then used as founding breeders to establish colonies useful as model systems of mitochondrial-nuclear interaction and disease susceptibility (e.g., females from these colonies are used to establish mitochondrial-nuclear exchanged colonies of any transgenic animal currently available for biomedical research).
- nDNA mitochondrial DNA
- nDNA nuclear DNA
- a subject susceptible to a disease or disorder refers to a subject having or at risk for developing one or more symptoms associated with the disease or disorder.
- subjects susceptible to the disease or disorder have an increased rate of occurrence or a faster onset of one or more symptoms of the disease or disorder as compared to a wild-type subject.
- Subjects susceptible to the disease or disorder may have a family history or known genetic predisposition for developing the disease or disorder.
- wild-type subjects refer to subjects without the disease or disorder and without enhanced resistance or susceptibility to a disease or disorder of interest.
- a subject resistant to the disease or disorder refers to a subject less likely to develop the disease or disorder than a wild-type subject.
- subjects resistant to the disease or disorder have a decreased rate of occurrence or a lower onset of the disease or disorder as compared to a wild-type subject.
- Subjects resistant to the disease or disorder can include partial or total resistance as compared to wild-type subject.
- a subject can be referred to as wild-type in the context of one disease or disorder while referred to as susceptible in the context of another disease or disorder.
- a subject can be referred to as wild-type in the context of cancer, but referred to as susceptible in the context of cardiovascular disease. In other words, the subject is not prone to cancer but is prone to cardiovascular disease.
- mtDNA mitochondrial DNA
- nDNA nuclear DNA
- the disease or disorder is, for example, cancer, cardiovascular disease, diabetes, neurological disorder, aging, metabolic disorder, immune disorder, obesity, and musculoskeletal disorder.
- the cell is an oocyte or an embryonic cell.
- zygotes and embryos such as pro-nuclear embryos comprising the cells.
- the cells are obtained from any animal including, mammals, birds and amphibians. Suitable mammalian sources include sheep, bovines, ovines, pigs, horses, rabbits, guinea pigs, mice, hamsters, rats, primates, and the like.
- Suitable mammalian sources include sheep, bovines, ovines, pigs, horses, rabbits, guinea pigs, mice, hamsters, rats, primates, and the like.
- the pro-nuclear embryos are obtained from mice.
- the cells are not human cells.
- human and animal cells useful in the present disclosure include, by way of example, epithelial, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle cells.
- the human cells used for nuclear exchange may be obtained from different organs, e.g., skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urethra and other urinary organs, and the like.
- suitable donor and recipient cells may be obtained from any cell or organ of the body. This includes all somatic or germ cells.
- Such a screening method comprises the steps of providing a mitochondrial-nuclear exchanged cell, tissue or organ, contacting the cell, tissue or organ with a candidate agent to be tested and determining whether the agent prevents or reduces one or more symptoms of the disease or disorder.
- the cells, tissues or organs are obtained from a mitochondrial-nuclear exchanged animal. Suitable tissues and organs include, skin, lung, muscle, cartilage, bone, bone marrow, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urinary organs, and the like.
- cardiovascular disease is associated with increased levels of oxidants, and an agent useful in treating cardiovascular disease causes decreased levels of oxidants.
- the determining step is, optionally, determining the level of oxidants in the cells.
- the determining step includes assessing mitochondrial function in the cells to determine whether the agent is useful in treating the disease or disorder. Such methods are known and are described in the Examples below.
- cancer is associated with increased cellular proliferation as compared to wild-type cells.
- the determining step is, optionally, determining the rate of proliferation of the cells.
- Such methods allow one skilled in the art to select candidate agents that are useful in treating, reducing or preventing one or more symptoms of the disease or disorder.
- agents may be useful as active ingredients included in pharmaceutical compositions for treating a subject suffering from the disease or disorder.
- chimeric animals comprising a plurality of the provided cells. Such chimeric animals are also referred to herein as mitochondrial-nuclear exchanged animals.
- chimeric animals comprising mitochondrial DNA (mtDNA) from a subject susceptible to a disease or disorder and nuclear DNA (nDNA) from a subject that is not susceptible to the disease or disorder.
- chimeric animals comprising mtDNA from a subject resistant to a disease or disorder and nDNA from a wild-type subject or a subject that is susceptible to the disease or disorder.
- the animal is a mouse comprising mtDNA from C57BL/6J mice and nDNA from C3H/HeN mice.
- the animal is a mouse comprising mtDNA from C3H/HeN mice and nDNA from C57BL/6J mice.
- the animal is a mouse comprising mtDNA from NZB/B1NJ mice, C57BL/6J mice or AKR/J mice and nDNA from FVB/N-TgN(MMTVPyMT) mice.
- the animal is a mouse comprising mtDNA from NZB/B1NJ mice and nDNA from C57BL/6J mice.
- the animal is a mouse comprising mtDNA from C57BL/6J mice and nDNA from NZB/B1NJ mice.
- the term chimeric animal refers to non-human animals, including, mammals, amphibians and birds. Specifically, examples include sheep, feline, bovines, ovines, pigs, horses, rabbits, guinea pigs, mice, hamsters, rats, primates, and the like.
- the animal further comprises a mutation in a gene associated with the disease or disorder.
- the gene is not expressed or the protein expressed by the gene is non-functional.
- the animal optionally comprises a mutation in SOD2 or ApoE such that SOD2 or ApoE is not expressed or the protein expressed by the gene is non-functional.
- progeny of the chimeric animals and progeny animals resulting from a cross between the female chimeric animal and a knockout mouse wherein the knockout mouse comprises a mutation in at least one gene associated with the disease or disorder such that the gene is not expressed or the protein expressed by the gene is not functional.
- the knockout mouse is susceptible to the disease or disorder or resistant to the disease or disorder.
- the method comprises selecting an animal susceptible to a disease or disorder or an animal resistant to the disease or disorder; selecting an animal that is not susceptible to the disease or disorder or an animal that is not resistant to the disease or disorder; harvesting the pro-nuclear embryos from each of the animals; enucleating the embryos; transferring the nucleus from the embryo of the animal that is not susceptible to the disease or disorder to the enucleated embryo of the animal susceptible to the disease or disorder to make a resulting embryo, wherein the resulting embryo has mtDNA from the animal susceptible to the disease or disorder and the nDNA from the animal that is not susceptible to the disease or disorder; and transferring the resulting embryo into an appropriate host.
- the transferred embryo is then allowed to develop into a progeny animal.
- the progeny animal is a mitochondrial-nuclear exchanged animal.
- the animal that is not susceptible to the disease or disorder is from a wild-type animal or an animal resistant to the disease or disorder.
- the method further comprises selecting female mitochondrial-nuclear exchanged animals for further breeding.
- a method of generating progeny of the female mitochondrial-nuclear exchanged animals is provided by crossing the females with a knockout animal, wherein the knockout animal comprises a mutation in at least one gene associated with the disease or disorder such that the gene is not expressed or the protein expressed by the gene is not functional.
- the method further comprises selecting progeny animals of the cross that comprise mtDNA from the mitochondrial-nuclear exchanged animals and nDNA from the knockout mouse.
- the disease or disorder of interest is, optionally, cancer, cardiovascular disease, diabetes, neurological disorder, aging, metabolic disorder, immune disorder, obesity, or musculoskeletal disorder.
- Other disease and disorders are contemplated and can be of interest when animals with reduced resistance or enhanced susceptibility are accessible.
- mice known to be susceptible or resistant to specific diseases are obtained, for example, from the Jackson Laboratory or other commercial or non-commercial sources.
- mice used in the provided methods include, but are not limited to, C57BL/6J, C3H/HeN, AKR/J, FVB strains, BALB/c strains, A/J strains, 129 strains and DBA/2 strains. Wild-type animal models can also be obtained from commercial and non-commercial sources.
- 29 strains are listed in the Mouse Phenome Database as being susceptible to cancer.
- over 50 strains are listed in the Mouse Phenome Database as being susceptible to cardiovascular disease.
- a few mouse models are discussed in detail below; however, any subject susceptible, resistant or wild-type can be used in the provided methods to generate mitochondrial-nuclear exchanged animals.
- mice useful in the provided methods include, A/J mice, which are susceptible to cancers and resistant to cardiovascular disease.
- A/J mice have a high incidence of spontaneous lung adenomas, lung tumors that readily develop in response to carcinogens, and mammary adenocarcinomas.
- A/J mice fed an atherogenic diet 1.25% cholesterol, 0.5% cholic acid, and 15% fat
- A/J mice are resistant to diabetes, obesity, insulin resistance and glucose intolerance.
- FVB/N-TgN(MMTV-PyMT) mice carrying the (MMTV-PyVT) transgene are susceptible to cancer.
- C57BL/6 mice are commonly used as a general purpose strain and background strain. This strain is refractory to many tumors. C57BL/6J mice are also commonly used in the production of transgenic mice. This strain can be used as a wild-type strain in many contexts. However, the C57BL/6J strain can be used in the context of cardiovascular disease as a susceptible animal since C57BL/6J mice are highly susceptibility to diet-induced obesity, type 2 diabetes, and atherosclerosis. Thus, C57BL/6J mice can be considered a subject susceptible to obesity, diabetes or cardiovascular disease or as a wild-type subject in the study of other diseases such as immunological diseases or cancer.
- NZB/B1NJ mice display a number of autoimmune abnormalities including hemolytic anemia, elevated levels of immunoglobulin, anti-DNA antibodies, anti-thymocyte antibodies, and circulating immune complexes causing glomerulonephritis.
- F1 hybrids of NZB/B1NJ and NZW/LacJ are used as a model for autoimmune disease resembling human systemic lupus erythematosus.
- NZB/B1NJ mice can be used as animals susceptible to autoimmune disorders or as animals resistant to cardiovascular disease.
- mice known to be susceptible (NZB/B1NJ) to automimmune disorders will be used in nuclear exchange experiments to generate mice with a NZB/B1NJ mtDNA haplotype and a nuclear genome of a normal mouse or a mouse resistant to autoimmune disorders. These mice are generated using the method set forth in Example 1 below.
- AKR/J mice are widely used in cancer research for their high leukemia incidence. AKR/J mice, however, are relatively resistant to aortic lesion formation on a semi-synthetic high fat diet and are hyporesponsive to diets containing high levels of fat and cholesterol. Thus, AKR/J mice are referred to as resistant to cardiovascular disease, but susceptible to cancer, and can be used accordingly in the present methods and cells.
- DBA/2J is a widely used strain in a large number of research areas, including cardiovascular biology, neurobiology, and sensorineural research.
- DBA/2J mice show a low susceptibility to developing atherosclerotic aortic lesions (20 to 350 ⁇ m2 atherosclerotic aortic lesions/aortic cross-section) following 14 weeks on an atherogenic diet (1.25% cholesterol, 0.5% cholic acid and 15% fat). They also exhibit high-frequency hearing loss beginning roughly at the time of weaning/adolescence (between 3-4 weeks of age) and becoming severe by 2-3 months of age.
- DBA/2J mice also show an extreme intolerance to alcohol and morphine.
- DBA/2J mice can be used as susceptible to neurologic disorders and hearing loss, but resistant to cardiovascular disease and substance abuse or addiction.
- Methods of screening for agents useful for treating a disease or disorder comprising the steps of providing a mitochondrial-nuclear exchanged animal comprising mtDNA from an animal susceptible to the disease or disorder and nDNA from an animal not susceptible to the disease or disorder, administering to the animal an agent to be tested, and determining whether the agent prevents or reduces one or more symptoms of the disease or disorder.
- the animal not susceptible to the disease or disorder is a wild-type animal or an animal resistant to the disease or disorder.
- the disease or disorder is selected from the group consisting of cancer, cardiovascular disease, diabetes, neurological disorder, aging, metabolic disorder, immune disorder, obesity, and musculoskeletal disorder.
- the disease is cancer and the mitochondrial-nuclear exchanged animal is a mouse comprising mtDNA from a mouse selected from the group consisting of FVB/N-TgN(MMTVPyMT), AKR/J, and A/J mice.
- the disease is cardiovascular disease and the mitochondrial-nuclear exchanged animal is a mouse comprising mtDNA from C57BL/6J or DBA/2J mice.
- the mitochondrial-nuclear exchanged animal is a mouse comprising mtDNA from C57BL/6J mice and NDNA from C3H/HeN mice.
- the mitochondrial-nuclear exchanged animal is a mouse comprising nDNA from a mouse selected from the group consisting of C57BL/6J, 129, A/J, BALB/c and C3H/HeN mice.
- any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods of using the disclosed compositions or animals. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.
- carcinogenic risk may be influenced by a combination of genetic and environmental factors that influence an individual's predilection to metastatic tumor formation.
- nuclear genetic differences may influence susceptibility to breast cancer; other reports suggest a potential role for the mitochondrion in influencing tumor metastatic potential.
- an important consideration currently lacking in determining individual susceptibility to breast cancer metastasis is the potential role for mitochondrial-nuclear interaction.
- Mitochondria have been implicated to play a significant role in the etiology of a variety of diseases, including cancer.
- Certain human mitochondrial DNA haplotypes appear to increase the risk for certain types of cancer and tumor growth in mice.
- Genetic background also influences metastatic mammary tumor formation in mice.
- mitochondrial-nuclear exchanged interaction influences metastatic susceptability, a molecular genetic approach was developed to investigate the role of mitochondrial genetic background on breast cancer metastasis.
- mice known to be resistant C57BL/6JN1cr
- metastasis in a metastatic mammary tumor model FVB/N-TgN(MMTVPyMT transgenic mouse
- FVB/N-TgN(MMTVPyMT transgenic mouse) were used in nuclear exchange experiments to generate mice with a C57BL/6J mtDNA haplotype and FVB/N-TgN nuclear genome and vice versa.
- fertilized oocytes were collected from C57BL/6JN1cr, and FVB/N-TgN(MMTVPyMT superovulated donor females. Enucleation of metaphase II oocytes and donor cell nuclear injections were conducted. Briefly, PMSG and hCG were administered to 4-6 wk old donor females, placed with stud males, and oocytes collected at 0.5 days post coitum (dpc). After cumulus cell removal, oocytes (15-20) were placed in a micromanipulation chamber containing M2 medium supplemented with cytoskeletal inhibitors cytochalasin B(5 ug/mL) and Colcemid(0.1 ug/mL) for 5-10 minutes.
- the zona pellucida is then “cored” using a single low duration high-intensity piezo-pulse (Primetech piezoelectric drill) from a ground 45 degree-angle enucleation pipette, both pronuclei were carefully aspirated and expelled.
- donor oocytes (those providing new nuclear material) were placed in the micromanipulation chamber, and pronuclei were again aspirated and immediately injected into the previously enucleated (recipient) oocytes.
- Reconstructed nuclear transfer embryos were then rinsed in fresh M2 media and electrofused in 25 uL droplets under oil. Reconstructed nuclear transfer embryos were immediately implanted into the oviducts of 0.5 dpc pseudopregnant females or cultured overnight to the 2-cell stage and then transferred. Surrogate mothers underwent C-sections if pups were not born naturally on their due date and fostered to ICR foster mothers.
- FIG. 1 shows the number of mitochondrial-nuclear exchanges performed resulting in term births, and surviving animals (6 weeks of age). Labels on the X-axis indicate mtDNA haplotype/nuclear genotype.
- PyMT refers to the FVB/N-TgN(MMTVPyMT) mouse.
- C57 refers to the C57BL/6JN1cr mouse.
- FIG. 2A shows a female mitochondrial-nuclear exchanged mouse [C57 mtDNA/FVB/N-TgN(MMTVPyMT) nuclear DNA (nDNA)] at 3 months of age.
- FIGS. 2B and 2C show mtDNA haplotyping gels (Asp I and Bcl I, respectively) to confirm mtDNA haplotype from ear clip DNA; lane 1 is the mouse in panel A.
- mitochondrial-nuclear exchange techniques can be used to successfully generate FVB/N-TgN(MMTVPyMT) transgenic mice on different mtDNA haplotype backgrounds, providing a novel means for direct assessment of mitochondrial-nuclear role(s) on cancer metastasis.
- MNX mitochondrial-nuclear exchange
- one female and three male MNX mice were generated with a C57BL/6J mtDNA and a PyMT nuclear FVB/N genome (mtDNAC57BL/6::nDNAPyMT) (Table 1).
- Wild-type mice develop mammary tumors and metastases with 100% penetrance within 70 days and 90 days, respectively.
- the MNX female mouse mtDNAC 57BL/6 ::nDNA PyMT
- 79 days slightly longer latency
- significantly fewer surface lung metastases 3 versus 25 for wild-type mice.
- MNX mice mtDNAC 57BL/6 ::nDNA PyMT
- only one has developed a mammary tumor (at 107 days), which is substantially longer than “wild-type” PyMT males (mean latency 83 days). When euthanized at 238 days, no metastases were found. The other two males were alive and tumor-free at 320+ days.
- mice known to be susceptible (AKR/J) or resistant (NZB/B1NJ) to metastasis in a metastatic mammary tumor model FVB/N-TgN(MMTVPyMT transgenic mouse) are used in nuclear exchange experiments to generate mice with a NZB/B1NJ mtDNA haplotype and FVB/N-TgN nuclear genome, and a mouse with a AKR/J mtDNA and FVB/N-TgN nuclear genome. These mice are assessed for metastatic tumor formation compared to mice with FVB mtDNA and FVB/N-TgN nuclear genomes. These mice are generated using the method set forth in Example 1.
- C57BL/6J mice are prone to cardiovascular disease while C3H/HeN mice are not.
- C3H mice have increased sensitivity to endothelial dependent vasorelaxation compared to C57 mice. Because C57 mice are more susceptible to atherogenesis compared to C3H mice, it was hypothesized that endothelial dependent vasorelaxation would be decreased in C57 mice relative to C3H mice. Consequently, vessel dilatation studies were performed on C57BL/6 and C3H/HeN mouse aortas harvested from 12 week old mice.
- 3A , 3 B and 3 C reveal that C3H mice were more sensitive to acetylcholine induced relaxation, whereas no differences were observed in endothelial independent relaxation (SNP), consistent with the hypothesis that C57 mice have decreased endothelial dependent vessel relaxation compared to C3H animals.
- SNP endothelial independent relaxation
- mice were generated that have the mtDNA of a susceptible strain (C57) and the NDNA of a resistant strain (C3H) and vice versa.
- FIG. 4A shows 6 female mice generated by mitochondrial-nuclear exchange using C57 and C3H pronuclear embryos. The 5 mice with black coats have C57 black nuclear DNA, as confirmed by both coat color and typing of 38 strain specific SNPs. These mice also have C3H mouse mitochondrial DNAs ( FIGS. 4B and 4C : lanes 1,2 and 4-6), as determined by Asp I and Bcl I RFLP analyses ( FIG. 4B and 4C , respectively).
- the mouse with brown coat color (#3) has C3H nuclear DNA (confirmed by SNP analysis) and a C57 mtDNA ( FIG. 4B and 4C : Lane 3) by RFLP analysis. These results confirm the feasibility of the proposed mitochondrial-nuclear exchange experiments.
- mice Because it is known that certain mouse strains have differential susceptibilities to CVD development, mitochondrial function and genetics may be important factors in influencing individual CVD susceptibility differences. Such differences in mice known to be susceptible or resistant to CVD were determined. C57BL/6J mice, referred to in Example 4 as C57 mice, are susceptible to dietary induced atherogenesis, whereas C3H/HeN, referred to in Example 4 as C3H mice, are not.
- FIG. 7 shows a 385 bp PCR product from C57 and C3H mice digested with AspI restriction enzyme, indicating that the C57 and C3H mtDNAs are distinguishable.
- Val248 is conserved between C57 mice, rats, gorillas, humans, frogs and trout.
- FIG. 8A shows that C3H mitochondria had significantly decreased complex IV activity relative to C57 mitochondria.
- Immunoblot analyses ( FIG. 8B ) from aliquots used in the enzyme analysis revealed no significant differences in subunit II of complex IV, showing that the observed differences seen in the enzymatic activity were not due to differences in complex IV amounts.
- FIG. 9 shows that the RCR in C3H mice appeared decreased relative to the C57 mice, showing that mitochondrial oxidative phosphorylation was less “coupled” to oxygen consumption in the C3H mice, consistent with the hypothesis that C3H have less coupled mitochondria relative to C57 mice, and therefore, are resistant to the oxidant stress associated with CVD risk factors.
- the ADP/O ratio relative to the C57BL/6J mouse mitochondrial control (determined from 5 independent experiments; 2 ⁇ C57BL/6J and 2 ⁇ C3H/HeN mice per experiment), is presented in FIG. 6B , showing that C3H/HeN mice have significantly lower ADP/O ratios compared to C57BL/6J mice.
- Low ADP/O ratios reflect decreased efficiency of oxygen utilization to make ATP and, thus, less efficient mitochondria.
- JC-1 fluorescence was utilized to determine mitochondrial membrane potentials. JC-1 exists as a green fluorescent monomer at low concentrations or low membrane potential, whereas at higher concentrations (>0.1 ⁇ m) it forms a red-fluorescent “J-aggregate.” Consequently, the ratio of red-to-green JC-1 fluorescence is dependent only on the mitochondrial membrane potential and not on other factors that may influence single-component fluorescence signals, such as mitochondrial size, shape and density.
- FIG. 10 shows that mitochondria isolated from C57 mouse hearts had significantly higher membrane potentials than age matched (10-week old) C3H mitochondria.
- FIG. 11 shows that a high fat diet significantly increased mtDNA damage in C57 mice, whereas damage was not significantly increased in the C3H mouse.
- FIG. 12 shows that C57 mitochondria exhibited significantly higher levels of fluorescence compared to C3H mitochondria, consistent with increased oxidant production.
- SOD2 or uncoupling proteins could explain, in part, the observed differences between C3H and C57 mitochondria.
- SOD2 protein or enzymatic activity or UCP levels were assessed, as were UCP 2 and 3 transcript levels (RT-PCR) from aortas and hearts from 10-week old C57 and C3H mice. No differences were found, suggesting that the differences between C57 and C3H mice were not due to changes in SOD2 or UCP 2 or 3 levels.
- FIG. 13 shows that C3H mice were more sensitive to acetylcholine induced vasorelaxation, consistent with the principal that these animals had greater NO bioavailability by virtue of decreased mitochondrial oxidant production.
- FIGS. 14A , 14B and 14C show that vascular function segregates with mitochondrial haplotype in mitochondrial-nuclear exchange mice.
- 14 week old mitochondrial-nuclear exchange male C3H mtDNA /C57 nDNA and C57 mtDNA /C3H nDNA mice were used in vessel relaxation studies and compared to age-matched wild-type C57BL/6 (C57 mtDNA /C57 nDNA ) and C3H/HeN (C3H mtDNA /C3H nDNA ) male mice.
- FIGS. 14A , 14 B and 14 C show that while all groups responded to PE induced vessel contraction equally ( FIG.
- FIG. 15 shows a mtDNA phylogeny with indication of relative CVD susceptibilities (susceptible, resistant, very resistant) for each strain of mouse.
- the mtDNA phylogenetic relationships appear to reflect the relative susceptibility to CVD development, consistent with the hypothesis that mitochondrial genetics plays a role in CVD susceptibility.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- The present application claims priority to U.S. Provisional Application No. 61/076,260, filed Jun. 27, 2008, which is incorporated by reference herein in its entirety.
- This invention was made with government support under Grant No. W91XWH-07-1-0540 awarded by the Department of Defense. The government has certain rights in the invention.
- Each cell contains hundreds of mitochondria and thousands of mitochondrial DNA (mtDNA) copies, which are maternally inherited. The mammalian mtDNA encodes 13 polypeptides that are essential for oxidative phosphorylation (OXPHOS) plus two rRNAs (12S and 16S) and 22 tRNAs that are required for mitochondrial protein synthesis. The mtDNA encoded polypeptide genes are structural subunits for four of the five OXPHOS enzyme complexes (I, III, IV and V). The nuclear DNA (nDNA) codes for all other mitochondrial proteins including all four subunits of complex II (succinate dehydrogenase), the mitochondrial DNA polymerase y subunits, the mitochondrial RNA polymerase components, the mitochondrial transcription factor (mtTFA), the mitochondrial ribosomal proteins and elongation factors, and the mitochondrial metabolic enzymes. Mitochondria generate energy via OXPHOS which “couples” electron transport with proton translocation for the production of ATP. Mitochondria are also the primary source of endogenous cellular ROS. The efficacy of mitochondrial energy and oxidant production is dependent upon a number of factors including local concentrations of both reactive nitrogen and oxygen species, mitochondrial antioxidants, cytokines, electron transport efficiency, metabolic reducing equivalent availability (NADH and FADH2), uncoupling protein (UCP) activities, and overall organelle integrity (damage to membranes, DNA, and proteins).
- Provided herein are cells and animals comprising mitochondrial DNA (mtDNA) from a subject susceptible to a disease or disorder and nuclear DNA (nDNA) from a subject that is not susceptible to the disease or disorder. Also provided are cells and animals comprising mitochondrial DNA (mtDNA) from a subject resistant to a disease or disorder and nuclear DNA (nDNA) from a wild-type subject or a subject that is susceptible to the disease or disorder. Such animals are referred to herein as mitochondrial-nuclear exchanged animals. Also provided are progeny of mitochondrial-nuclear exchanged animals and progeny animals resulting from a cross between the mitochondrial-nuclear exchanged animals and a knockout mouse, wherein the knockout mouse comprises a mutation in at least one gene associated with the disease or disorder such that the gene is not expressed or the protein expressed by the gene is not functional.
- Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. The method comprises selecting an animal susceptible to a disease or disorder, selecting an animal that is not susceptible to the disease or disorder, harvesting pro-nuclear embryos from the animals, enucleating the embryos, transferring the nucleus from the animal that is not susceptible to the disease or disorder to the enucleated embryo of the animal susceptible to the disease or disorder, wherein the embryo has mtDNA from the animal susceptible to the disease or disorder and the NDNA from the animal that is not susceptible to the disease or disorder, and transferring the embryo into an appropriate host and allowing the transferred embryo to develop into a progeny animal, wherein the progeny animal is a mitochondrial-nuclear exchanged animal.
- Also provided is a method of screening for agents useful for treating a disease or disorder comprising the steps of providing a mitochondrial-nuclear exchanged animal comprising mtDNA from an animal susceptible to the disease or disorder and nDNA from an animal not susceptible to the disease or disorder, administering to the animal an agent to be tested, and determining whether the agent prevents or reduces one or more symptoms of the disease or disorder.
- The details of one or more aspects are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.
-
FIG. 1 shows the number of mitochondrial-nuclear exchanges performed resulting in term births, and surviving animals (6 weeks of age). Labels on the X-axis indicate mtDNA haplotype/nuclear genotype. PyMT refers to the FVB/N-TgN(MMTVPyMT) mouse. C57 refers to the C57BL/6JN1cr mouse. -
FIG. 2A shows a female mitochondrial-nuclear exchanged mouse [C57 mtDNA/FVB/N-TgN(MMTVPyMT) nuclear DNA (nDNA)] at 3 months of age. -
FIGS. 2B and 2C show mtDNA haplotyping gels (Asp I and Bcl I, respectively) to confirm mtDNA haplotype from ear clip DNA;lane 1 is the mouse inFIG. 2A . -
FIGS. 3A , 3B and 3C are graphs showing isometric tension measured in aortic segments from 12-week old male C57 and C3H mice. Thoracic aorta were cut into 2 mm ring segments and suspended from a force-displacement transducer in an isolated tissue bath. To assess endothelium-dependent relaxation, indomethacin-treated rings were contracted with phenylephrine (PE) (FIG. 3A ) followed by addition of acetylcholine (Ach) (FIG. 3B ). Sodium nitroprusside (SNP) was added to contracted rings to determine endothelial independent relaxation (FIG. 3C ). Relaxation was quantified as percent decrease in vessel tension of the pre-existing tone generated by PE. Data are the mean from 3-4 ring segments from each animal (N=4 mice/group). Asterisks (*) indicate significant difference (P<0.05) between the two mouse strains. -
FIG. 4A shows mice generated from mitochondrial-nuclear exchange. Coat color indicates nDNA genome (C3H—brown, C57—black), which has been confirmed via SNP analysis of 38 markers (Jackson Labs, Bar Harbor, Me.). Numbers on mice indicate mtDNA RFLP analyses inFIGS. 4B and 4C .Number 3, brown coat, is the mouse with nDNA from C3H and mtDNA from C57 mice. -
FIG. 4B shows AspI RFLP analysis verifying mtDNA genotype. PCR products from C57 mtDNAs were cleaved by AspI to yield 274 bp and 111 bp fragments, whereas C3H mtDNAs were uncut (385 bp). -
FIG. 4C shows BclI RFLP analysis verifying mtDNA genotype. PCR products from C57 mtDNAs were uncut (204 bp) whereas C3H mtDNAs were cleaved by BclI to yield 166 bp and 38 bp fragments. -
FIG. 5 is a schematic summarizing the process of creating mitochondrial-nuclear exchanged animals. -
FIG. 6A shows polarographic trace of isolated heart mitochondria.State 3 respiration is initiated by addition substrate (glutamate+malate) and ADP (125 nmoles) and total O2 consumption determined until the return tostate 4 respiration (occurs when all the ADP is consumed by phosphorylation to ATP). Addition of oligomycin abolishes ADP-induced respiratory stimulation which is subsequently relieved by the uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP). -
FIG. 6B is a graph showing the ADP/O ratio of C57BL/6J (C57) and C3H/HeN (C3H) mice relative to C57BL/6J control mitochondria. The ADP/O ratio is calculated as the ratio of nanomoles of ADP added, to nanoatoms of oxygen consumed duringstate 3 respiration. Data are expressed relative to the C57BL/6J control mitochondria because results were obtained from 5 independent experiments, with C57BL/6J mitochondria serving as the control for each separate experiment (N=2 per strain per experiment). The ADP/O mean+SE over all experiments was C57−2.88+0.05; C3H−2.39+0.04). Asterisk (*) indicates a significant difference (P<0.05) exists from C3H/HeN mouse mitochondria. -
FIG. 7 shows RFLP analysis of mtDNA COIII subunit. Specifically, a gel of AspI restriction digest of 385 bp PCR products from C57 and C3H mice is shown. The C57 mtDNA was cleaved into 274 bp and 111 bp, whereas the C3H mtDNA was not. -
FIGS. 8A and 8B show cytochrome c oxidase activities in C57 and C3H mice. Mitochondria were prepared from whole aortas harvested from 10-week old male C57BL6 and C3H/HeN mice. InFIG. 8A , complex IV activity was determined by measuring the oxidation of reduced cytochrome c at 550 nm (37° C.) in isolated mitochondria. Asterisks (*) indicate a significant difference exists between C57 and C3H mitochondria. InFIG. 8B , immunoblot analysis showing the relative level of complex IV subunit II from an aliquot of the samples used for complex IV activity. -
FIG. 9 shows Respiratory Control Ratios (RCR) in C57 and C3H mouse hearts. Mitochondria were isolated from age-matched (10 week old) C57and C3H mouse hearts, and oxygen consumption determined in the presence of an electron donor (glutamate/malate) with and without ADP (state state 3 respiration rate divided bystate 4 respiration rate); C3H hearts had significantly lower RCR values, indicating that oxygen utilization (in terms of generating ATP) by the mitochondrion is less efficient in the C3H hearts. N=3/group. -
FIG. 10 is a bar graph showing mitochondrial membrane potentials in C57 and C3H mice. Mitochondria were prepared from hearts harvested from 10-week old male C57BL6 and C3H/HeN mice (fed chow diets) and JC-1 fluorescence determined at 535 nm and 590 nm emissions on aCytoFluor 4000 fluorometer. Asterisks (*) indicate that a significant difference exists between C57 and C3H mitochondria. -
FIG. 11 shows the effect of diet on mtDNA damage in aortas from C57 and C3H mice. Male C57 and C3H mice were fed either chow or high fat diets (4% or 21% fat, respectively) from 6-10 weeks of age. DNA was extracted from aortas and QPCR was performed to quantify mtDNA damage. Asterisks (* or **) indicate significant differences (P<0.05) exist from chow fed C57 or high fat C3H, respectively. N=3 per group. -
FIG. 12 shows relative levels of Amplex Red fluorescence from mitochondria isolated from C57 and C3H mouse aortas. 10-week old male C57 and C3H mice were sacrificed, and mitochondria isolated from aortas (2 aortas were pooled/sample). 50 μg of mitochondrial protein were incubated with glutamate/malate, ADP, Amplex Red, and HRP. Relative fluorescence indicates increased oxidant production in C57 mitochondria relative to C3H. Asterisks (*) indicate significant differences (P<0.05) exist. N=6 mice, or 3 samples (C57); N=6 mice, or 3 samples (C3H). -
FIG. 13 shows isometric tension measured in aortic segments from 12-week old male C57 and C3H mice. Briefly, thoracic aorta were cut into 2 mm ring segments and suspended from a force-displacement transducer in an isolated tissue bath. To assess endothelium-dependent, NO-mediated relaxation, indomethacin-treated rings were contracted with phenylephrine followed by addition of acetylcholine. Relaxation was 20674-0101001 quantified as percent decrease in vessel tension of the pre-existing tone generated by phenylephrine. Data are the mean from 3-4 ring segments from each animal (N=4 mice/group). Asterisks (*) indicate significant difference (P<0.05) between the two mouse strains. -
FIGS. 14A , 14B and 14C are graphs showing isometric tension measured in aortic segments from 14-week old male C57mtDNA/C57nDNA; C3HmtDNA/C3HnDNA; C3HmDNA/C57nDNA; and C57mtDNA/C3HnDNA mice. To assess endothelium-dependent, NO-mediated relaxation, indomethacin-treated rings were contracted with phenylephrine (PE) (FIG. 14A ) followed by addition of acetylcholine (Ach) (FIG. 14B ). Sodium nitroprusside (SNP) was added to contracted rings to determine endothelial independent relaxation (FIG. 14C ). Relaxation was quantified as percent decrease in vessel tension of the pre-existing tone generated by PE. Data are the mean from 3-4 ring segments from each animal (N=3 mice/group). Asterisks (* and **) indicate significant difference (P<0.05) between the C57mtDNA/C57nDNA and C57mtDNA/C3HnDNA, respectively. -
FIG. 15 shows mtDNA phylogeny derived from known mtDNA sequences from mice (GenBank) also known to have differential susceptibility to cardiovascular disease (CVD). CVD susceptibility is characterized as “Very Resistant,” “Resistant,” and “Susceptible” based upon review of the literature; “very resistant” indicates no atherosclerotic lesion formation, “resistant” indicates modest lesion formation relative to the “susceptible” C57 mouse. Amino acid or tRNA changes are indicated next to the location of each mtDNA mutation. - MtDNA mutations have been linked with human disease. For example, studies have shown that specific mtDNA mutations and haplotypes are associated with increased risk for diseases thought or known to have an environmental component in humans (e.g., deafness, blindness, Alzheimer's disease, diabetes and cancer). Similarly, studies have shown that the mtDNA haplotype can influence tumor growth and age-related deafness in mice. Mitochondrial haplotypes thought to be associated with tightly coupled mitochondria appear to be more prone to certain types of cancer and neurodegenerative diseases associated with oxidative stress and/or somatic mutation. Because it is difficult to examine multiple molecular mechanisms related to many of the aforementioned aspects of mitochondria (e.g., damage, membrane potential, oxidant stress, respiratory activity and enzyme function) in human populations, animal models are required to test the molecular aspects of the mitochondrial-nuclear interaction in determining individual disease susceptibility.
- Thus, provided herein are chimeric animals, or cells, tissues or organs thereof with the mitochondrial DNA (mtDNA) from of one cell type (genetic background) and the nuclear DNA (NDNA) from of another cell type, also referred to herein as mitochondrial-nuclear exchanged animals, cells, tissues or organs. Within the cell, mitochondria and the nucleus interact in a manner that ultimately determines how the cell will function and respond to various endogenous and exogenous factors. Consequently, how mitochondria and the nucleus interact determines an individual's susceptibility to disease and the individual's ability to adapt to changes in the environment. Hence, the provided methods allow exchange of mitochondrial and nuclear genetic materials (i.e., putting a cell nucleus into a cytoplasm containing mitochondria that are typically not associated with that nuclear DNA) and model systems for determining how mtDNA impacts disease development and susceptibility to factors associated with disease risk and adaptation to general environmental changes. The provided chimeric models and cells are used to determine the mechanistic and genetic basis of disease susceptibility and resistance (e.g., cardiovascular disease, cancer, diabetes, musculoskeletal, neurological, obesity, aging, fitness, and the like).
-
FIG. 5 summarizes the process of creating mitochondrial-nuclear exchanged animals. Specifically, pro-nuclear embryos are harvested from genetically distinct donors (in terms of mitochondrial and nuclear DNAs), enucleated, and the nucleus from one donor is introduced into the enucleated cell of the other, generating an re-nucleated embryo with the nuclear DNA from one strain (e.g., strain B) and the mitochondrial DNAs (e.g., strain A) from the other. These embryos are implanted into surrogate mothers who carry the transgenic embryo to term. The genetic identity of the progeny is confirmed via genotyping tail and ear clips from the offspring. Females of desired mtDNA-nDNA genotype are then used as founding breeders to establish colonies useful as model systems of mitochondrial-nuclear interaction and disease susceptibility (e.g., females from these colonies are used to establish mitochondrial-nuclear exchanged colonies of any transgenic animal currently available for biomedical research). - Provided are animals, cells, tissues or organs comprising mitochondrial DNA (mtDNA) from a subject susceptible to a disease or disorder and nuclear DNA (nDNA) from a subject that is not susceptible to the disease or disorder. Optionally, the nDNA is from a wild-type subject. Optionally, the nDNA is from a subject resistant to the disease or disorder.
- As used herein, a subject susceptible to a disease or disorder refers to a subject having or at risk for developing one or more symptoms associated with the disease or disorder. Thus, subjects susceptible to the disease or disorder have an increased rate of occurrence or a faster onset of one or more symptoms of the disease or disorder as compared to a wild-type subject. Subjects susceptible to the disease or disorder may have a family history or known genetic predisposition for developing the disease or disorder. As used herein, wild-type subjects refer to subjects without the disease or disorder and without enhanced resistance or susceptibility to a disease or disorder of interest. As used herein, a subject resistant to the disease or disorder refers to a subject less likely to develop the disease or disorder than a wild-type subject. Thus, subjects resistant to the disease or disorder have a decreased rate of occurrence or a lower onset of the disease or disorder as compared to a wild-type subject. Subjects resistant to the disease or disorder can include partial or total resistance as compared to wild-type subject. Further a subject can be referred to as wild-type in the context of one disease or disorder while referred to as susceptible in the context of another disease or disorder. For example, a subject can be referred to as wild-type in the context of cancer, but referred to as susceptible in the context of cardiovascular disease. In other words, the subject is not prone to cancer but is prone to cardiovascular disease.
- Also provided are animals, cells, tissues or organs comprising mitochondrial DNA (mtDNA) from a subject resistant to a disease or disorder and nuclear DNA (nDNA) from a wild-type subject or a subject that is susceptible to the disease or disorder.
- The disease or disorder is, for example, cancer, cardiovascular disease, diabetes, neurological disorder, aging, metabolic disorder, immune disorder, obesity, and musculoskeletal disorder. Optionally, the cell is an oocyte or an embryonic cell. Also provided are zygotes and embryos, such as pro-nuclear embryos comprising the cells.
- Optionally, the cells are obtained from any animal including, mammals, birds and amphibians. Suitable mammalian sources include sheep, bovines, ovines, pigs, horses, rabbits, guinea pigs, mice, hamsters, rats, primates, and the like. Optionally, the pro-nuclear embryos are obtained from mice. Optionally, the cells are not human cells.
- Other human and animal cells useful in the present disclosure include, by way of example, epithelial, neural cells, epidermal cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B and T lymphocytes), erythrocytes, macrophages, monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle cells. Moreover, the human cells used for nuclear exchange may be obtained from different organs, e.g., skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urethra and other urinary organs, and the like. These are just examples of suitable donor and recipient cells. Suitable donor and recipient cells may be obtained from any cell or organ of the body. This includes all somatic or germ cells.
- Methods of screening for agents useful for treating a disease or disorder are provided. Such a screening method comprises the steps of providing a mitochondrial-nuclear exchanged cell, tissue or organ, contacting the cell, tissue or organ with a candidate agent to be tested and determining whether the agent prevents or reduces one or more symptoms of the disease or disorder. Optionally, the cells, tissues or organs are obtained from a mitochondrial-nuclear exchanged animal. Suitable tissues and organs include, skin, lung, muscle, cartilage, bone, bone marrow, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urinary organs, and the like.
- By way of example, cardiovascular disease is associated with increased levels of oxidants, and an agent useful in treating cardiovascular disease causes decreased levels of oxidants. Thus, the determining step is, optionally, determining the level of oxidants in the cells. Alternatively, the determining step includes assessing mitochondrial function in the cells to determine whether the agent is useful in treating the disease or disorder. Such methods are known and are described in the Examples below. By way of another example, cancer is associated with increased cellular proliferation as compared to wild-type cells. Thus, the determining step is, optionally, determining the rate of proliferation of the cells.
- Such methods allow one skilled in the art to select candidate agents that are useful in treating, reducing or preventing one or more symptoms of the disease or disorder. Such agents may be useful as active ingredients included in pharmaceutical compositions for treating a subject suffering from the disease or disorder.
- Also provided are chimeric animals comprising a plurality of the provided cells. Such chimeric animals are also referred to herein as mitochondrial-nuclear exchanged animals. Thus, provided herein are chimeric animals comprising mitochondrial DNA (mtDNA) from a subject susceptible to a disease or disorder and nuclear DNA (nDNA) from a subject that is not susceptible to the disease or disorder. Also provided herein are chimeric animals comprising mtDNA from a subject resistant to a disease or disorder and nDNA from a wild-type subject or a subject that is susceptible to the disease or disorder. By way of example, the animal is a mouse comprising mtDNA from C57BL/6J mice and nDNA from C3H/HeN mice. Optionally, the animal is a mouse comprising mtDNA from C3H/HeN mice and nDNA from C57BL/6J mice. By way of another example, the animal is a mouse comprising mtDNA from NZB/B1NJ mice, C57BL/6J mice or AKR/J mice and nDNA from FVB/N-TgN(MMTVPyMT) mice. By way of another example, the animal is a mouse comprising mtDNA from NZB/B1NJ mice and nDNA from C57BL/6J mice. Optionally, the animal is a mouse comprising mtDNA from C57BL/6J mice and nDNA from NZB/B1NJ mice.
- As used herein, the term chimeric animal refers to non-human animals, including, mammals, amphibians and birds. Specifically, examples include sheep, feline, bovines, ovines, pigs, horses, rabbits, guinea pigs, mice, hamsters, rats, primates, and the like. Optionally, the animal further comprises a mutation in a gene associated with the disease or disorder. Optionally, the gene is not expressed or the protein expressed by the gene is non-functional. For example, the animal optionally comprises a mutation in SOD2 or ApoE such that SOD2 or ApoE is not expressed or the protein expressed by the gene is non-functional.
- Also provided are progeny of the chimeric animals and progeny animals resulting from a cross between the female chimeric animal and a knockout mouse, wherein the knockout mouse comprises a mutation in at least one gene associated with the disease or disorder such that the gene is not expressed or the protein expressed by the gene is not functional. Optionally, the knockout mouse is susceptible to the disease or disorder or resistant to the disease or disorder.
- Also provided are methods for producing a mitochondrial-nuclear exchanged animal and a mitochondrial-nuclear exchanged animal made by the provided method. The method comprises selecting an animal susceptible to a disease or disorder or an animal resistant to the disease or disorder; selecting an animal that is not susceptible to the disease or disorder or an animal that is not resistant to the disease or disorder; harvesting the pro-nuclear embryos from each of the animals; enucleating the embryos; transferring the nucleus from the embryo of the animal that is not susceptible to the disease or disorder to the enucleated embryo of the animal susceptible to the disease or disorder to make a resulting embryo, wherein the resulting embryo has mtDNA from the animal susceptible to the disease or disorder and the nDNA from the animal that is not susceptible to the disease or disorder; and transferring the resulting embryo into an appropriate host. The transferred embryo is then allowed to develop into a progeny animal. The progeny animal is a mitochondrial-nuclear exchanged animal. Optionally, the animal that is not susceptible to the disease or disorder is from a wild-type animal or an animal resistant to the disease or disorder. Optionally, the method further comprises selecting female mitochondrial-nuclear exchanged animals for further breeding.
- A method of generating progeny of the female mitochondrial-nuclear exchanged animals is provided by crossing the females with a knockout animal, wherein the knockout animal comprises a mutation in at least one gene associated with the disease or disorder such that the gene is not expressed or the protein expressed by the gene is not functional. Optionally, the method further comprises selecting progeny animals of the cross that comprise mtDNA from the mitochondrial-nuclear exchanged animals and nDNA from the knockout mouse.
- In the provided methods, the disease or disorder of interest is, optionally, cancer, cardiovascular disease, diabetes, neurological disorder, aging, metabolic disorder, immune disorder, obesity, or musculoskeletal disorder. Other disease and disorders are contemplated and can be of interest when animals with reduced resistance or enhanced susceptibility are accessible.
- Methods of nuclear exchange are known and include the methods described in the examples below and those described in, for example, U.S. Publication No. 2003/0032180; U.S. Publication No. 2005/0120402; U.S. Publication No. 2005/0095704; and U.S. Patent No. 6,603,059, which are incorporated by reference herein in their entireties. Nuclear exchange is also described in U.S. Pat. Nos. 4,944,384; 5,057,420; Campbell et al., Theriogenology, 43:181 (1995); Collas et al., Mol. Report Dev., 38:264-267 (1994); Keefer et al., Biol. Reprod., 50:935-939 (1994); Sims et al., Proc. Natl. Acad. Sci., USA, 90:6143-6147 (1993); WO 94/26884; WO 94/24274, and WO 90/03432, which are incorporated by reference in their entireties herein.
- Animals known to be susceptible or resistant to specific diseases are obtained, for example, from the Jackson Laboratory or other commercial or non-commercial sources. By way of example, mice used in the provided methods include, but are not limited to, C57BL/6J, C3H/HeN, AKR/J, FVB strains, BALB/c strains, A/J strains, 129 strains and DBA/2 strains. Wild-type animal models can also be obtained from commercial and non-commercial sources. Mouse models known to be susceptible to specific diseases are listed in the Mouse Phenome Database at http://phenome.jax.org/pub-cgi/phenome/mpdcgi?rtn=docs/home, which is incorporated herein by reference in its entirety. For example, 29 strains are listed in the Mouse Phenome Database as being susceptible to cancer. By way of another example, over 50 strains are listed in the Mouse Phenome Database as being susceptible to cardiovascular disease. A few mouse models are discussed in detail below; however, any subject susceptible, resistant or wild-type can be used in the provided methods to generate mitochondrial-nuclear exchanged animals.
- Mice useful in the provided methods include, A/J mice, which are susceptible to cancers and resistant to cardiovascular disease. A/J mice have a high incidence of spontaneous lung adenomas, lung tumors that readily develop in response to carcinogens, and mammary adenocarcinomas. A/J mice fed an atherogenic diet (1.25% cholesterol, 0.5% cholic acid, and 15% fat) fail to develop atherosclerotic aortic lesions in contrast to several highly susceptible strains of mice. In addition to atherosclerosis resistance, A/J mice are resistant to diabetes, obesity, insulin resistance and glucose intolerance.
- FVB/N-TgN(MMTV-PyMT) mice carrying the (MMTV-PyVT) transgene are susceptible to cancer.
- C57BL/6 mice are commonly used as a general purpose strain and background strain. This strain is refractory to many tumors. C57BL/6J mice are also commonly used in the production of transgenic mice. This strain can be used as a wild-type strain in many contexts. However, the C57BL/6J strain can be used in the context of cardiovascular disease as a susceptible animal since C57BL/6J mice are highly susceptibility to diet-induced obesity,
type 2 diabetes, and atherosclerosis. Thus, C57BL/6J mice can be considered a subject susceptible to obesity, diabetes or cardiovascular disease or as a wild-type subject in the study of other diseases such as immunological diseases or cancer. - NZB/B1NJ mice display a number of autoimmune abnormalities including hemolytic anemia, elevated levels of immunoglobulin, anti-DNA antibodies, anti-thymocyte antibodies, and circulating immune complexes causing glomerulonephritis. F1 hybrids of NZB/B1NJ and NZW/LacJ (NZBWF1/J) are used as a model for autoimmune disease resembling human systemic lupus erythematosus. NZB/B1NJ mice, fed an atherogenic diet (1.25% cholesterol, 0.5% cholic acid and 15% fat), fail to develop atherosclerotic aortic lesions. NZB/B1NJ mice can be used as animals susceptible to autoimmune disorders or as animals resistant to cardiovascular disease. By way of example, mice known to be susceptible (NZB/B1NJ) to automimmune disorders will be used in nuclear exchange experiments to generate mice with a NZB/B1NJ mtDNA haplotype and a nuclear genome of a normal mouse or a mouse resistant to autoimmune disorders. These mice are generated using the method set forth in Example 1 below.
- AKR/J mice are widely used in cancer research for their high leukemia incidence. AKR/J mice, however, are relatively resistant to aortic lesion formation on a semi-synthetic high fat diet and are hyporesponsive to diets containing high levels of fat and cholesterol. Thus, AKR/J mice are referred to as resistant to cardiovascular disease, but susceptible to cancer, and can be used accordingly in the present methods and cells.
- DBA/2J is a widely used strain in a large number of research areas, including cardiovascular biology, neurobiology, and sensorineural research. DBA/2J mice show a low susceptibility to developing atherosclerotic aortic lesions (20 to 350 μm2 atherosclerotic aortic lesions/aortic cross-section) following 14 weeks on an atherogenic diet (1.25% cholesterol, 0.5% cholic acid and 15% fat). They also exhibit high-frequency hearing loss beginning roughly at the time of weaning/adolescence (between 3-4 weeks of age) and becoming severe by 2-3 months of age. DBA/2J mice also show an extreme intolerance to alcohol and morphine. Thus, DBA/2J mice can be used as susceptible to neurologic disorders and hearing loss, but resistant to cardiovascular disease and substance abuse or addiction.
- Methods of screening for agents useful for treating a disease or disorder are provided comprising the steps of providing a mitochondrial-nuclear exchanged animal comprising mtDNA from an animal susceptible to the disease or disorder and nDNA from an animal not susceptible to the disease or disorder, administering to the animal an agent to be tested, and determining whether the agent prevents or reduces one or more symptoms of the disease or disorder. Optionally, the animal not susceptible to the disease or disorder is a wild-type animal or an animal resistant to the disease or disorder. Optionally, the disease or disorder is selected from the group consisting of cancer, cardiovascular disease, diabetes, neurological disorder, aging, metabolic disorder, immune disorder, obesity, and musculoskeletal disorder. Optionally, the disease is cancer and the mitochondrial-nuclear exchanged animal is a mouse comprising mtDNA from a mouse selected from the group consisting of FVB/N-TgN(MMTVPyMT), AKR/J, and A/J mice. Optionally, the disease is cardiovascular disease and the mitochondrial-nuclear exchanged animal is a mouse comprising mtDNA from C57BL/6J or DBA/2J mice. Optionally, the mitochondrial-nuclear exchanged animal is a mouse comprising mtDNA from C57BL/6J mice and NDNA from C3H/HeN mice. Optionally, the mitochondrial-nuclear exchanged animal is a mouse comprising nDNA from a mouse selected from the group consisting of C57BL/6J, 129, A/J, BALB/c and C3H/HeN mice.
- Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a chimeric animal is disclosed and discussed and a number of modifications that can be made to the chimeric animal are discussed, each and every combination and permutation of the chimeric animal, and the modifications that are possible are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods of using the disclosed compositions or animals. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.
- Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.
- A number of aspects have been described. Nevertheless, it will be understood that various modifications may be made. Furthermore, when one characteristic or step is described it can be combined with any other characteristic or step herein even if the combination is not explicitly stated. Accordingly, other aspects are within the scope of the claims.
- It is widely appreciated that carcinogenic risk may be influenced by a combination of genetic and environmental factors that influence an individual's predilection to metastatic tumor formation. In this respect, numerous studies have investigated and reported that nuclear genetic differences may influence susceptibility to breast cancer; other reports suggest a potential role for the mitochondrion in influencing tumor metastatic potential. In this regard, an important consideration currently lacking in determining individual susceptibility to breast cancer metastasis is the potential role for mitochondrial-nuclear interaction.
- Mitochondria have been implicated to play a significant role in the etiology of a variety of diseases, including cancer. Certain human mitochondrial DNA haplotypes appear to increase the risk for certain types of cancer and tumor growth in mice. Genetic background also influences metastatic mammary tumor formation in mice. To test whether mitochondrial-nuclear exchanged interaction influences metastatic susceptability, a molecular genetic approach was developed to investigate the role of mitochondrial genetic background on breast cancer metastasis. Specifically, mice known to be resistant (C57BL/6JN1cr) to metastasis in a metastatic mammary tumor model (FVB/N-TgN(MMTVPyMT transgenic mouse) were used in nuclear exchange experiments to generate mice with a C57BL/6J mtDNA haplotype and FVB/N-TgN nuclear genome and vice versa.
- Specifically, fertilized oocytes were collected from C57BL/6JN1cr, and FVB/N-TgN(MMTVPyMT superovulated donor females. Enucleation of metaphase II oocytes and donor cell nuclear injections were conducted. Briefly, PMSG and hCG were administered to 4-6 wk old donor females, placed with stud males, and oocytes collected at 0.5 days post coitum (dpc). After cumulus cell removal, oocytes (15-20) were placed in a micromanipulation chamber containing M2 medium supplemented with cytoskeletal inhibitors cytochalasin B(5 ug/mL) and Colcemid(0.1 ug/mL) for 5-10 minutes. Using a holding pipette to immobilize an oocyte, the zona pellucida is then “cored” using a single low duration high-intensity piezo-pulse (Primetech piezoelectric drill) from a ground 45 degree-angle enucleation pipette, both pronuclei were carefully aspirated and expelled. When all oocytes had been enucleated, donor oocytes (those providing new nuclear material) were placed in the micromanipulation chamber, and pronuclei were again aspirated and immediately injected into the previously enucleated (recipient) oocytes. Reconstructed nuclear transfer embryos were then rinsed in fresh M2 media and electrofused in 25 uL droplets under oil. Reconstructed nuclear transfer embryos were immediately implanted into the oviducts of 0.5 dpc pseudopregnant females or cultured overnight to the 2-cell stage and then transferred. Surrogate mothers underwent C-sections if pups were not born naturally on their due date and fostered to ICR foster mothers.
-
FIG. 1 shows the number of mitochondrial-nuclear exchanges performed resulting in term births, and surviving animals (6 weeks of age). Labels on the X-axis indicate mtDNA haplotype/nuclear genotype. PyMT refers to the FVB/N-TgN(MMTVPyMT) mouse. C57 refers to the C57BL/6JN1cr mouse. -
FIG. 2A shows a female mitochondrial-nuclear exchanged mouse [C57 mtDNA/FVB/N-TgN(MMTVPyMT) nuclear DNA (nDNA)] at 3 months of age.FIGS. 2B and 2C show mtDNA haplotyping gels (Asp I and Bcl I, respectively) to confirm mtDNA haplotype from ear clip DNA;lane 1 is the mouse in panel A. - These data shown mitochondrial-nuclear exchange techniques can be used to successfully generate FVB/N-TgN(MMTVPyMT) transgenic mice on different mtDNA haplotype backgrounds, providing a novel means for direct assessment of mitochondrial-nuclear role(s) on cancer metastasis. As an example of the feasibility of using the mitochondrial-nuclear exchange (MNX) mouse model, one female and three male MNX mice were generated with a C57BL/6J mtDNA and a PyMT nuclear FVB/N genome (mtDNAC57BL/6::nDNAPyMT) (Table 1). Because F1 progeny from PyMT ♂ X C57BL/6 ♀ have a suppressed metastasis index, it was thought that MNX mtDNAC57BL/6::nDNAPyMT mice would have suppressed tumor formation and metastatic potential compared to mice harboring the FVB/N mtDNA (the “wild-type” mtDNA for the PyMT transgenic) and PyMT nuclear genome (mtDNAFVB/N::nDNAPyMT).
-
TABLE 1 A summary of the study from the first four mtDNAC57BL/6::nDNAPyMT mice produced. Onset of Primary Number of Lung Gender Age Breast Tumor Metastases MNX Femalea 110 days at sacrifice 79 days 3 MNX Malea 238 days at sacrifice 107 days None detected MNX Malea Currenlty 308 days, not None detected ND yet sacrificed MNX Malea Currently 308 days, not None detected ND yet sacrificed Female controlsb 94 ± 2.35 days at 67.22 ± 3.07 days 24.63 ± 5.39 sacrifice Male controlsb,c Average age at 83 ± 20 days Specific number not sacrifice not provided reported, multiple, 80% penetrance ND—not determined amtDNAC57B1/6::nDNAPyMT mice bmtDNAFVB/N::nDNAPyMT mice; Control data are listed as mean + SEM cMale control data are from Hazen and Heinecke, J. Clin. Invest. 99: 2075-2081 (1997). - “Wild-type” (mtDNAFVB/N::nDNAPyMT) mice develop mammary tumors and metastases with 100% penetrance within 70 days and 90 days, respectively. The MNX female mouse (mtDNAC57BL/6::nDNAPyMT) exhibited slightly longer latency (79 days), but significantly fewer surface lung metastases (3 versus 25 for wild-type mice). Of the three male MNX mice (mtDNAC57BL/6::nDNAPyMT) generated, only one has developed a mammary tumor (at 107 days), which is substantially longer than “wild-type” PyMT males (mean latency 83 days). When euthanized at 238 days, no metastases were found. The other two males were alive and tumor-free at 320+ days.
- These data show that pre-existent normal mitochondrial haplotypes or polymorphisms influence breast cancer latency and metastatic efficiency.
- Mice known to be susceptible (AKR/J) or resistant (NZB/B1NJ) to metastasis in a metastatic mammary tumor model (FVB/N-TgN(MMTVPyMT transgenic mouse) are used in nuclear exchange experiments to generate mice with a NZB/B1NJ mtDNA haplotype and FVB/N-TgN nuclear genome, and a mouse with a AKR/J mtDNA and FVB/N-TgN nuclear genome. These mice are assessed for metastatic tumor formation compared to mice with FVB mtDNA and FVB/N-TgN nuclear genomes. These mice are generated using the method set forth in Example 1.
- As described herein, mitochondrial-nuclear exchange successfully generated mice with mtDNAs of one strain and the nDNA of another. C57BL/6J mice are prone to cardiovascular disease while C3H/HeN mice are not. C3H mice have increased sensitivity to endothelial dependent vasorelaxation compared to C57 mice. Because C57 mice are more susceptible to atherogenesis compared to C3H mice, it was hypothesized that endothelial dependent vasorelaxation would be decreased in C57 mice relative to C3H mice. Consequently, vessel dilatation studies were performed on C57BL/6 and C3H/HeN mouse aortas harvested from 12 week old mice.
FIGS. 3A , 3B and 3C reveal that C3H mice were more sensitive to acetylcholine induced relaxation, whereas no differences were observed in endothelial independent relaxation (SNP), consistent with the hypothesis that C57 mice have decreased endothelial dependent vessel relaxation compared to C3H animals. - To test the hypothesis that the noted differences in mouse strain susceptibility to CVD are related to mtDNA haplotype, mice were generated that have the mtDNA of a susceptible strain (C57) and the NDNA of a resistant strain (C3H) and vice versa.
FIG. 4A shows 6 female mice generated by mitochondrial-nuclear exchange using C57 and C3H pronuclear embryos. The 5 mice with black coats have C57 black nuclear DNA, as confirmed by both coat color and typing of 38 strain specific SNPs. These mice also have C3H mouse mitochondrial DNAs (FIGS. 4B and 4C :lanes FIG. 4B and 4C , respectively). The mouse with brown coat color (#3) has C3H nuclear DNA (confirmed by SNP analysis) and a C57 mtDNA (FIG. 4B and 4C : Lane 3) by RFLP analysis. These results confirm the feasibility of the proposed mitochondrial-nuclear exchange experiments. - Because it is known that certain mouse strains have differential susceptibilities to CVD development, mitochondrial function and genetics may be important factors in influencing individual CVD susceptibility differences. Such differences in mice known to be susceptible or resistant to CVD were determined. C57BL/6J mice, referred to in Example 4 as C57 mice, are susceptible to dietary induced atherogenesis, whereas C3H/HeN, referred to in Example 4 as C3H mice, are not.
- Experiments were performed to distinguish between the two mtDNA haplotypes of C57 and C3H. In this respect, C57 and C3H differed at nt 9348 within the COIII gene (G to A, resulting in the change of a highly conserved Val248 to Ile248 in C57 to C3H, respectively). This change abolishes a AspI site in the C3H mtDNA.
FIG. 7 shows a 385 bp PCR product from C57 and C3H mice digested with AspI restriction enzyme, indicating that the C57 and C3H mtDNAs are distinguishable. Val248 is conserved between C57 mice, rats, gorillas, humans, frogs and trout. - To determine whether the missense mutation in cytochrome oxidase subunit III conveyed any functional effects upon electron transport, mitochondria were isolated from C3H and C57 mice (fed chow diets) and assessed for complex IV activity.
FIG. 8A shows that C3H mitochondria had significantly decreased complex IV activity relative to C57 mitochondria. Immunoblot analyses (FIG. 8B ) from aliquots used in the enzyme analysis revealed no significant differences in subunit II of complex IV, showing that the observed differences seen in the enzymatic activity were not due to differences in complex IV amounts. These findings were consistent with the concept that there will be functional differences between the atherogenic susceptible C57 and resistant C3H mice. - To determine whether the mitochondria from C3H mice were different from C57 in terms of oxygen utilization and ATP generation, respiratory control ratios (RCR =
state 3/state 4 respiration; oxygen consumption rates in the presence and absence of ADP, respectively) were quantified from mitochondria isolated from heart tissues harvested from male C3H and C57 mice on chow diets.FIG. 9 shows that the RCR in C3H mice appeared decreased relative to the C57 mice, showing that mitochondrial oxidative phosphorylation was less “coupled” to oxygen consumption in the C3H mice, consistent with the hypothesis that C3H have less coupled mitochondria relative to C57 mice, and therefore, are resistant to the oxidant stress associated with CVD risk factors. - To evaluate the relative efficiencies of mitochondrial ATP generation coupled to oxygen consumption in C57BL/6J and C3H/HeN mice, 10−C57BL/6J and 10−C3H/HeN mice were harvested at 14 weeks of age over a series of 5 days (N=2 C57BL/6J, and 2−C3H/HeN mice per experiment, per day), and a known amount of ADP (125 nmoles) was added to equal amounts of heart mitochondria isolated from C57 or C3H mice to induce
state 3 respiration (malate/glutamate+ADP). The amount of oxygen consumed was quantified to the point of return tostate 4 respiration (occurs when all the ADP is consumed by phosphorylation to ATP:FIG. 6A ). The ADP/O ratio relative to the C57BL/6J mouse mitochondrial control (determined from 5 independent experiments; 2−C57BL/6J and 2−C3H/HeN mice per experiment), is presented inFIG. 6B , showing that C3H/HeN mice have significantly lower ADP/O ratios compared to C57BL/6J mice. Low ADP/O ratios reflect decreased efficiency of oxygen utilization to make ATP and, thus, less efficient mitochondria. These results showed that C3H/HeN mitochondria consumed more oxygen compared to C57BL/6J mitochondria, per ADP molecule phosphorylated, consistent with the hypothesis that C3H/HeN mice are less energetically efficient compared to C57BL/6J mice. - Because the data above suggested that differences existed between the mitochondria from C3H and C57 mice, JC-1 fluorescence was utilized to determine mitochondrial membrane potentials. JC-1 exists as a green fluorescent monomer at low concentrations or low membrane potential, whereas at higher concentrations (>0.1 μm) it forms a red-fluorescent “J-aggregate.” Consequently, the ratio of red-to-green JC-1 fluorescence is dependent only on the mitochondrial membrane potential and not on other factors that may influence single-component fluorescence signals, such as mitochondrial size, shape and density.
FIG. 10 shows that mitochondria isolated from C57 mouse hearts had significantly higher membrane potentials than age matched (10-week old) C3H mitochondria. These findings are consistent with the hypothesis that C3H mice have mitochondria that are less coupled than those of C57 mice. - Because the data above were consistent with the hypothesis that C3H mice were less coupled relative to C57 mice, the impact of a high fat diet on mtDNA damage was assessed in aortic tissues from both C57 and C3H mice. Male C3H and C57 mice were fed either a chow or high fat diet from 6 to 10 weeks of age, and mtDNA damage was determined from aortas.
FIG. 11 shows that a high fat diet significantly increased mtDNA damage in C57 mice, whereas damage was not significantly increased in the C3H mouse. - To determine whether differences in oxidant levels existed between mitochondria from C57 and C3H mice, isolated mitochondria were assessed for oxidant generation by Amplex Red fluorescence (in the presence of HRP, reacts with H2O2).
FIG. 12 shows that C57 mitochondria exhibited significantly higher levels of fluorescence compared to C3H mitochondria, consistent with increased oxidant production. - Increased levels of SOD2 or uncoupling proteins (UCPs) could explain, in part, the observed differences between C3H and C57 mitochondria. To determine whether differences in SOD2 protein or enzymatic activity or UCP levels existed, SOD2 activity and protein levels were assessed, as were
UCP UCP - Because data suggested that C57 mitochondria were more tightly coupled than C3H, and that higher oxidant production (presumably O2−) appeared to be associated with C57 mitochondria, it was hypothesized that endothelial dependent vasorelaxation would be inhibited in C57 mice relative to C3H mice (due to increased oxidant stress).
FIG. 13 shows that C3H mice were more sensitive to acetylcholine induced vasorelaxation, consistent with the principal that these animals had greater NO bioavailability by virtue of decreased mitochondrial oxidant production. -
FIGS. 14A , 14B and 14C show that vascular function segregates with mitochondrial haplotype in mitochondrial-nuclear exchange mice. To evaluate the impact the mitochondrial genetic background on vascular function, 14 week old mitochondrial-nuclear exchange male C3HmtDNA/C57nDNA and C57mtDNA/C3HnDNA mice were used in vessel relaxation studies and compared to age-matched wild-type C57BL/6 (C57mtDNA/C57nDNA) and C3H/HeN (C3HmtDNA/C3HnDNA) male mice.FIGS. 14A , 14B and 14C show that while all groups responded to PE induced vessel contraction equally (FIG. 14A ), significant differences in endothelial dependent vessel relaxation occurred between groups, with relaxation segregating with mtDNA haplotype (FIG. 14B ). No significant differences were observed in endothelial independent vessel relaxation (FIG. 14C ). These data support the notion that the mtDNA haplotype can contribute significantly to endothelial dependent vessel function, and moreover, are consistent with the hypothesis that mitochondrial function and genetics are important factors in influencing individual CVD susceptibility. - Based upon their known mtDNA sequences, phylogenetic analyses were performed to determine the potential phylogenetic relationships among strains of mice that were known to have different susceptibilities to CVD development.
FIG. 15 shows a mtDNA phylogeny with indication of relative CVD susceptibilities (susceptible, resistant, very resistant) for each strain of mouse. The mtDNA phylogenetic relationships appear to reflect the relative susceptibility to CVD development, consistent with the hypothesis that mitochondrial genetics plays a role in CVD susceptibility. - In summary, these data collectively show that the CVD resistant C3H/HeN mouse has mitochondrial characteristics that make it less susceptible to cardiovascular disease. Further, these studies show that mitochondrial function and genetics are important factors in influencing individual CVD susceptibility.
Claims (49)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/486,375 US20090328241A1 (en) | 2008-06-27 | 2009-06-17 | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
US13/360,344 US9040771B2 (en) | 2008-06-27 | 2012-01-27 | Nonhuman mammal whose mtDNA is from a nonhuman mammal resistant to a selected disease or disorder and whose nDNA is from a nonhuman donor mammal more susceptible to the selected disease or disorder |
US14/697,243 US9592306B2 (en) | 2008-06-27 | 2015-04-27 | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7626008P | 2008-06-27 | 2008-06-27 | |
US12/486,375 US20090328241A1 (en) | 2008-06-27 | 2009-06-17 | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/360,344 Continuation US9040771B2 (en) | 2008-06-27 | 2012-01-27 | Nonhuman mammal whose mtDNA is from a nonhuman mammal resistant to a selected disease or disorder and whose nDNA is from a nonhuman donor mammal more susceptible to the selected disease or disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090328241A1 true US20090328241A1 (en) | 2009-12-31 |
Family
ID=41449367
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/486,375 Abandoned US20090328241A1 (en) | 2008-06-27 | 2009-06-17 | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
US13/360,344 Active US9040771B2 (en) | 2008-06-27 | 2012-01-27 | Nonhuman mammal whose mtDNA is from a nonhuman mammal resistant to a selected disease or disorder and whose nDNA is from a nonhuman donor mammal more susceptible to the selected disease or disorder |
US14/697,243 Active US9592306B2 (en) | 2008-06-27 | 2015-04-27 | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/360,344 Active US9040771B2 (en) | 2008-06-27 | 2012-01-27 | Nonhuman mammal whose mtDNA is from a nonhuman mammal resistant to a selected disease or disorder and whose nDNA is from a nonhuman donor mammal more susceptible to the selected disease or disorder |
US14/697,243 Active US9592306B2 (en) | 2008-06-27 | 2015-04-27 | Mitochondrial-nuclear exchanged cells, tissues, organs and animals |
Country Status (1)
Country | Link |
---|---|
US (3) | US20090328241A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057420A (en) * | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
US20030032180A1 (en) * | 2000-07-29 | 2003-02-13 | Strelchenko Larissa V. | Reconstituted cell lines prepared by nuclear transfer between differentiated cells |
US6603059B1 (en) * | 1997-03-06 | 2003-08-05 | Infigen, Inc. | Method of cloning animals |
US20040107454A1 (en) * | 2002-07-31 | 2004-06-03 | Wheeler Matthew B. | Nuclear transfer with embryonic stem cells |
US20050095704A1 (en) * | 1996-08-19 | 2005-05-05 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US20050120402A1 (en) * | 2002-01-14 | 2005-06-02 | Justin St. John | Cloning methods and other methods of producing cells |
US20050250203A1 (en) * | 1996-08-19 | 2005-11-10 | James Robl | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US20060236416A1 (en) * | 2002-02-27 | 2006-10-19 | Yasumitsu Nagao | Embryonically modified animal and method of constructing the same |
US7361804B1 (en) * | 1997-02-19 | 2008-04-22 | Roslin Institute (Edinburgh) | Unactivated oocytes in nuclear transfer to produce ungulates |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8907666A (en) | 1988-09-21 | 1991-07-30 | Cambridge Animal Biotech | DERIVATION OF PLURIPOTENTIAL EMBRYO CELL LINES FROM DOMESTIC ANIMALS |
GB9308271D0 (en) | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
-
2009
- 2009-06-17 US US12/486,375 patent/US20090328241A1/en not_active Abandoned
-
2012
- 2012-01-27 US US13/360,344 patent/US9040771B2/en active Active
-
2015
- 2015-04-27 US US14/697,243 patent/US9592306B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057420A (en) * | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
US20050095704A1 (en) * | 1996-08-19 | 2005-05-05 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US20050250203A1 (en) * | 1996-08-19 | 2005-11-10 | James Robl | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US7361804B1 (en) * | 1997-02-19 | 2008-04-22 | Roslin Institute (Edinburgh) | Unactivated oocytes in nuclear transfer to produce ungulates |
US6603059B1 (en) * | 1997-03-06 | 2003-08-05 | Infigen, Inc. | Method of cloning animals |
US20030032180A1 (en) * | 2000-07-29 | 2003-02-13 | Strelchenko Larissa V. | Reconstituted cell lines prepared by nuclear transfer between differentiated cells |
US20050120402A1 (en) * | 2002-01-14 | 2005-06-02 | Justin St. John | Cloning methods and other methods of producing cells |
US20060236416A1 (en) * | 2002-02-27 | 2006-10-19 | Yasumitsu Nagao | Embryonically modified animal and method of constructing the same |
US20040107454A1 (en) * | 2002-07-31 | 2004-06-03 | Wheeler Matthew B. | Nuclear transfer with embryonic stem cells |
Also Published As
Publication number | Publication date |
---|---|
US20150231278A1 (en) | 2015-08-20 |
US9592306B2 (en) | 2017-03-14 |
US9040771B2 (en) | 2015-05-26 |
US20140250542A1 (en) | 2014-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220256822A1 (en) | Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes | |
Wallace et al. | Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease | |
WO2018177351A1 (en) | Method for preparing non-chimeric gene knockout animal based on crispr/cas9 technology | |
US20180084767A1 (en) | Animal models for cardiomyopathy | |
CN110438160B (en) | Construction method and application of Cd2ap gene knockout animal | |
Suganuma et al. | Tn5 transposase-mediated mouse transgenesis | |
US10568974B2 (en) | Animal models of atherosclerosis | |
Kalds et al. | When less is more: targeting the Myostatin gene in livestock for augmenting meat production | |
Nilsson et al. | Transient expression of a human β‐actin promoter/lacZ gene introduced into mouse embryos correlates with a low degree of methylation | |
EA030305B1 (en) | Animal model of krabbe's disease | |
US9592306B2 (en) | Mitochondrial-nuclear exchanged cells, tissues, organs and animals | |
CN114457114B (en) | Construction method of animal model for conditional knockout of Fars2 gene | |
US20110054247A1 (en) | Methods for cloning ferrets and transgenic ferret models for diseases | |
US6784336B2 (en) | Method of producing mutant mice | |
Yin et al. | Dynamic characteristics of the mitochondrial genome in SCNT pigs | |
CN110283851B (en) | Target MYO9B related to malignant pleural effusion and application thereof | |
KR101348852B1 (en) | Mis18α knockout mouse model and producing method thereof | |
US20060265772A1 (en) | Histamine hyperproductive animal | |
US8203030B2 (en) | Transgenic mouse models for diseases caused by mtDNA mutations and related methods | |
US7518033B2 (en) | Methods for the production of cells and mammals with desired genetic modifications | |
US6177610B1 (en) | Major basic protein deficient animals | |
US20190183100A1 (en) | Animal models for polycystic kidney disease | |
JP2001169684A (en) | Uridine phosphorylase-expression-deficient animal | |
CN116376976A (en) | Construction method and application of humanized IL32 gamma conditional knock-in mouse model | |
CN116042714A (en) | Construction method and application of METTL7B gene lung specificity knock-in mouse model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UAB RESEARCH FOUNDATION, ALABAMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALLINGER, SCOTT WEBSTER;WELCH, DANNY R.;KESTERSON, ROBERT ALLEN;AND OTHERS;REEL/FRAME:022927/0064;SIGNING DATES FROM 20080715 TO 20080922 |
|
AS | Assignment |
Owner name: US ARMY, SECRETARY OF THE ARMY, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:023710/0621 Effective date: 20091223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:051566/0893 Effective date: 20100108 |
|
AS | Assignment |
Owner name: ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:051568/0584 Effective date: 20200108 |
|
AS | Assignment |
Owner name: ARMY/MRMC, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ALABAMA AT BIRMINGHAM;REEL/FRAME:058382/0304 Effective date: 20211213 |